A
APGE

AlphaQuest’s Apogee Therapeutics APGE Stock Holding History

AlphaQuest’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,524
Closed -$191K – 138
2025
Q4 		$191K Sell
2,524
-2,387
-49% -$150K 0.01% 1476
2025
Q3 		$195K Sell
4,911
-162
-3% -$6.19K 0.01% 1416
2025
Q2 		$220K Buy
5,073
+3,932
+345% +$150K 0.02% 1066
2025
Q1 		$42.6K Buy
+1,141
New +$44.1K ﹤0.01% 1559

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

AlphaQuest's APGE Position: Q1 2026 in Review

AlphaQuest sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 2,524 shares — an estimated $191K sold.

AlphaQuest first reported a position in APGE in Q1 2025 and held it in 4 quarters. The position peaked at $220K in Q2 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • AlphaQuest reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 2,524 Apogee Therapeutics shares in Q1 2026, an estimated $191K.
  • AlphaQuest first reported a position in Apogee Therapeutics in Q1 2025 and held it in 4 quarters.
  • AlphaQuest's Apogee Therapeutics position peaked at $220K in Q2 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.